Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Thumbnail

Delayed discharge after TAVR growing less common, tied to worse outcomes

Patients who remain in the hospital for longer than three days following transcatheter aortic valve replacement (TAVR) are at a 45 percent increased risk of death within one year versus those discharged sooner after the procedure, a new analysis found.

Thumbnail

TAVR/TMVR market projected to reach $8B by 2023

The global market for transcatheter treatment of the mitral and aortic valves is expected to double over the next five years, according to a new report from BCC Research. The industry analysis projects an increase from $4 billion in 2018 to $8 billion in 2023, at a compound annual growth rate (CAGR) of 14.8 percent.

2 years after study finds Celebrex heart-safe, research links drug to valve calcification

More than two years after a major New England Journal of Medicine study declared arthritis drug Celebrex safe for use in heart patients, new research published in JACC: Basic to Translational Science Feb. 22 suggests the drug might actually raise users’ risk for heart valve calcification.

Edwards’ Pascal TMVR system gains CE mark

The Pascal transcatheter mitral valve repair (TMVR) system has received its CE mark for the treatment of patients with mitral regurgitation, device manufacturer Edwards Lifesciences announced Feb. 19.

Clopidogrel loading offers little added benefit for stenosis patients pre-TAVI

P2Y12 inhibitor initiation with clopidogrel using a loading dose (LD) is no more effective in reducing ischemic events or adverse outcomes in transcatheter aortic valve implantation (TAVI) patients than initiating the therapy without a loading dose, according to research published in the American Journal of Cardiology Feb. 10.

Thumbnail

Oral antibiotics on par with IV delivery for endocarditis

A Danish study of 400 patients with infective endocarditis has concluded oral delivery of antibiotics to treat the disease yields similar safety and efficiency as administering the drugs intravenously.

Thumbnail

Classifying cardiac changes pre-TAVR may boost risk stratification

A four-stage system that quantifies the extent of cardiac changes associated with aortic stenosis was linked to the odds of death and readmission following transcatheter aortic valve replacement (TAVR), a finding that may aid cardiologists in making prognoses and engaging in shared decision-making with patients.

TAVR tied to shorter hospital stays, better outcomes for patients in their 80s

Although octogenarians undergoing transcatheter or surgical aortic valve replacement (TAVR or SAVR) experienced similar rates of in-hospital mortality and vascular complications, a recent analysis from the National Inpatient Sample concluded patients who received the less-invasive procedure had shorter hospital stays and fared better for a range of other outcomes.

Displaying 761 - 768 of 874
Design by Adaptive Theme